StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com

Q/C Technologies Gets Nasdaq Notice Over Sub-$1 Bid Price

Q/C Technologies received a Nasdaq letter on Nov. 6, 2026 saying its share price had closed below $1 for 30 straight business days, triggering a 180-day compliance period.

What happened

Q/C Technologies, Inc. (ticker QCLS) said in a Form 8-K filed Nov. 13, 2026 that it received a letter from Nasdaq's Listing Qualifications staff on Nov. 6, 2026 notifying it that it no longer meets a continued listing requirement.

According to the filing, the company's stock closed below $1.00 per share for 30 consecutive business days, from Sept. 25, 2026 to Nov. 5, 2026. That fails Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.

The filing states Nasdaq has given the company a 180-calendar-day compliance period, running until May 5, 2027, to regain compliance. The company said it is evaluating options and intends to regain compliance, but that there can be no assurance it will.

The filing does not explain why the share price has been trading below $1.00. It only reports the Nasdaq notice.

The company

Q/C Technologies, Inc. is incorporated in Delaware and lists its principal executive offices at 333 Bush Street, Suite 1400, San Francisco, California. Its common stock trades on the Nasdaq Capital Market under the symbol QCLS. The filing identifies the stock as having a par value of $0.001 per share.

The filing itself contains no description of the company's business or operations beyond its identity as the registrant.

What this means

Nasdaq Rule 5550(a)(2) is a price floor: to stay listed on the Nasdaq Capital Market, a company's shares must hold a closing bid price of at least $1.00. Nasdaq measures this over a rolling 30-business-day window, which is why the letter cites a specific date range — Sept. 25 to Nov. 5, 2026 — rather than a single day's close.

A 180-day compliance period is a grace window, not an immediate delisting. During it, the company stays listed. If the bid price closes at or above $1.00 for a sustained stretch, the deficiency is typically cured and the matter closed. The filing addresses the mechanics of a cure only in terms of the second 180-day window it may qualify for: if the company meets Nasdaq's market-value-of-publicly-held-shares standard and all other initial listing criteria except the bid price, and gives written notice it intends to cure, it could get an additional 180 days, potentially using a reverse stock split. A reverse split combines shares, which raises the per-share price without changing the company's overall value.

If compliance is not regained and the company is not eligible for the second window, the filing says Nasdaq will notify the company that its securities are subject to delisting.

Item 3.01 of Form 8-K is the specific disclosure item for a delisting notice or failure to satisfy a continued listing standard. The filing states the company disclosed the letter under Nasdaq Listing Rule 5810(b), which requires listed companies to publicly disclose receipt of such a notice within four business days.

Sources

Information summarized by AI from the sources listed above. May contain errors — informational only, not investment advice.